- Home
- RFIL vs VRCA Comparison
RFIL vs VRCA Comparison
Compare RFIL & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | VRCA |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 112.4M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RFIL | VRCA |
|---|---|---|
| Price | $11.30 | $5.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.25 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 143.6K | 129.4K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $7.07 | $372.93 |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $1,135.00 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $3.39 | $0.39 |
| 52 Week High | $12.24 | $9.82 |
Technical Indicators
Market Signals| Indicator | RFIL | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 34.60 |
| Support Level | $6.11 | $5.34 |
| Resistance Level | $12.07 | $6.44 |
| Average True Range (ATR) | 0.87 | 0.47 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 76.64 | 6.67 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.